Yamakawa Yuriko, Satoh Shinji, Sawa Shunji, Ohta Hitoshi, Asada Takashi
Ibaraki Prefectural University of Health Sciences School of Health Sciences, Ibaraki, Japan.
Psychiatry Clin Neurosci. 2005 Dec;59(6):705-10. doi: 10.1111/j.1440-1819.2005.01440.x.
Post-stroke depression (PSD) has a negative impact on rehabilitation following stroke. No satisfactory antidepressant treatment for PSD has yet been developed. The present study examined the effect of milnacipran, a serotonin and norepinephrine reuptake inhibitor, on PSD patients. Eleven PSD patients taking milnacipran in a rehabilitation hospital were compared to age-matched, sex-matched, and severity of depression at admission-matched PSD patients hospitalized during 2001 who did not take any antidepressant as historical control. Severity of depression was measured using self-rating depression scale for depression (SDS) assessed at admission and discharge after 3 months inpatient rehabilitation. Activities of daily living (ADL) and quality of life (QOL) were measured, respectively, by the functional independence measure (FIM) and a self-completed questionnaire for QOL (QUIK) as outcomes of rehabilitation. For the SDS score, the group taking milnacipran showed significant improvement compared to the control group in our study. FIM was improved in both groups. In the end QUIK did not change significantly in either group. We found no major side-effects of milnacipran among the patients. These results suggest that milnacipran is a safe and effective treatment for PSD for inpatients undergoing rehabilitation.
中风后抑郁症（PSD）对中风后的康复有负面影响。目前尚未开发出令人满意的PSD抗抑郁治疗方法。本研究考察了5-羟色胺与去甲肾上腺素再摄取抑制剂米那普明对PSD患者的疗效。将一家康复医院中11名服用米那普明的PSD患者与2001年住院的、年龄、性别及入院时抑郁严重程度相匹配但未服用任何抗抑郁药物的PSD患者作为历史对照进行比较。抑郁严重程度采用入院时及住院康复3个月出院时的抑郁自评量表（SDS）进行测量。分别采用功能独立性测量（FIM）和生活质量自评问卷（QUIK）测量日常生活活动能力（ADL）和生活质量（QOL），作为康复结果。对于SDS评分，在我们的研究中，服用米那普明的组与对照组相比有显著改善。两组的FIM均有所改善。最后，两组的QUIK均无显著变化。我们在患者中未发现米那普明的主要副作用。这些结果表明，米那普明对接受康复治疗的住院PSD患者是一种安全有效的治疗方法。
